A comparison of methods of plasmapheresis for the treatment of late antibody mediated rejection in kidney transplant recipients

被引:2
|
作者
Caliskan, Yasar [1 ,2 ]
Mirioglu, Safak [2 ,3 ]
Dirim, Ahmet Burak [2 ]
Ozluk, Yasemin [4 ]
Yegit, Ozan [2 ]
Aksoy, Elif [2 ]
Safak, Seda [2 ]
Guller, Nurana [2 ]
Demir, Erol [2 ]
Artan, Ayse Serra [2 ]
Oto, Ozgur Akin [2 ]
Besisik, Sevgi [5 ]
Yazici, Halil [2 ]
Turkmen, Aydin [2 ]
Lentine, Krista L. [1 ]
机构
[1] St Louis Univ, Sch Med, Ctr Abdominal Transplantat, 3660 Vista Ave, St Louis, MO 63110 USA
[2] Istanbul Univ, Istanbul Sch Med, Div Nephrol, Istanbul, Turkey
[3] Bezmialem Vakif Univ, Div Nephrol, Sch Med, Istanbul, Turkey
[4] Istanbul Univ, Istanbul Sch Med, Dept Pathol, Istanbul, Turkey
[5] Istanbul Univ, Istanbul Sch Med, Div Hematol, Istanbul, Turkey
关键词
antibody mediated rejection; kidney transplantation; plasmapheresis; rejection; HUMORAL REJECTION; ALLOGRAFT-REJECTION; PLASMA-EXCHANGE; RITUXIMAB; IMMUNOADSORPTION; OUTCOMES; THERAPY; RESCUE;
D O I
10.1111/1744-9987.13937
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction We compared the outcomes associated with plasma exchange (PE), double filtration plasmapheresis (DFPP), or immunoadsorption (IA) in the treatment of late antibody mediated rejection (AMR). Methods Sixty-nine kidney transplantation (KTx) recipients with late AMR were retrospectively categorized according to management with PE (n = 30), DFPP (n = 22) or IA (n = 17). Allograft loss was compared across treatment groups by Kaplan-Meier analysis and Cox regression. Results Study groups were similar regarding age, sex, donor type, kidney function, donor specific antibodies, and post-KTx follow-up time. Five-year graft survival trended higher with IA (70.6%) compared to PE (36.7%) and DFPP (27.3%) (p = 0.06). In multivariate Cox regression, baseline eGFR (HR per ml/min/1.73 m(2) [95% CI]; 0.96 [0.94-0.99]), rituximab use (HR [95% CI]; 0.42 [0.21-0.84]), interstitial inflammation (i) (HR [95% CI]; 2.05 [1.13-3.69]), and transplant glomerulopathy (cg) (HR [95% CI]; 1.46 [1.13-1.87]) were associated with graft loss. Conclusion These results motivate the need for continued assessment of rituximab and plasmapheresis in larger studies.
引用
收藏
页码:428 / 434
页数:7
相关论文
共 50 条
  • [41] Efficacy and Safety of Tocilizumab in the Treatment of Acute Active Antibody-mediated Rejection in Kidney Transplant Recipients
    Pottebaum, April A.
    Venkatachalam, Karthikeyan
    Liu, Chang
    Brennan, Daniel C.
    Murad, Haris
    Malone, Andrew F.
    Alhamad, Tarek
    TRANSPLANTATION DIRECT, 2020, 6 (04): : E543
  • [42] Treatment and Outcomes of Kidney Transplant Recipients with C4d Negative Antibody Mediated Rejection
    Walsh, M.
    Lineberger, L.
    Brokhof, M.
    Kenyon, N.
    Alvey, N.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2021, 21 : 734 - 734
  • [43] COMPARING PLASMAPHERESIS plus IVIG VS. PLASMAPHERESIS plus IVIG plus RITUXIMAB ON MANAGEMENT OF ANTIBODY-MEDIATED ACUTE REJECTION IN KIDNEY TRANSPLANT RECIPIENTS
    Dashti-Khavidaki, Simin
    Ahmadi, Fatemeh
    Khatami, Mohammad-Reza
    TRANSPLANT INTERNATIONAL, 2017, 30 : 293 - 293
  • [44] Outcomes in Kidney Transplant Recipients With Post-Transplant DSA in the Absence of Antibody Mediated Rejection
    Osadchuk, L.
    Astor, B.
    Ellis, T.
    Kaufman, D.
    Brar, J.
    Djamali, A.
    Muth, B.
    Mohamed, M.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2014, 14 : 467 - 467
  • [45] A Randomized Trial of Bortezomib in Late Antibody-Mediated Kidney Transplant Rejection
    Eskandary, Farsad
    Regele, Heinz
    Baumann, Lukas
    Bond, Gregor
    Kozakowski, Nicolas
    Wahrmann, Markus
    Hidalgo, Luis G.
    Haslacher, Helmuth
    Kaltenecker, Christopher C.
    Aretin, Marie-Bernadette
    Oberbauer, Rainer
    Posch, Martin
    Staudenherz, Anton
    Handisurya, Ammon
    Reeve, Jeff
    Halloran, Philip F.
    Boehmig, Georg A.
    JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2018, 29 (02): : 591 - 605
  • [46] Early Versus Late Acute Antibody-Mediated Rejection in Renal Transplant Recipients
    Dorje, Christina
    Midtvedt, Karsten
    Holdaas, Hallvard
    Naper, Christian
    Strom, Erik H.
    Oyen, Ole
    Leivestad, Torbjorn
    Aronsen, Tommy
    Jenssen, Trond
    Flaa-Johnsen, Linda
    Lindahl, Jorn Petter
    Hartmann, Anders
    Reisaeter, Anna Varberg
    TRANSPLANTATION, 2013, 96 (01) : 79 - 84
  • [47] Successful treatment of antibody mediated rejection with plasmapheresis and Rituximab
    Podder, Hemangshu
    Kerman, Ronald H.
    Katz, Stephan M.
    Knight, Richard J.
    Van Buren, Charles T.
    Acorda, Noriel
    Pollard, Vida
    McKissick, Eva
    Hosek, Kathleen
    Tu, T.
    Hoover, Angela
    Baron, Victor
    Kahan, Barry D.
    TRANSPLANT INTERNATIONAL, 2007, 20 : 132 - 132
  • [48] Outcomes of Treatment of Late Antibody-Mediated Rejection in Primary Renal Transplant Recipients - A Single Center Experience
    Prashar, R.
    Patel, A.
    Venkat, K.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2015, 15
  • [49] Conversion to Belatacept in kidney transplant recipients with chronic antibody-mediated rejection (CAMR)
    Moein, Mahmoudreza
    Gao, Shuqi X.
    Martin, Samuel J.
    Farkouh, Katie M.
    Li, Benson W.
    Ball, Angela S.
    Dvorai, Reut Hod
    Saidi, Reza F.
    TRANSPLANT IMMUNOLOGY, 2023, 76
  • [50] Antibody Mediated Rejection in Kidney Transplant Recipients with and without Donor Specific Antibodies.
    Miguel, M.
    Lai, J.
    Bray, R.
    Eckels, D.
    Gebel, H.
    Bry, W.
    Katznelson, S.
    Peddi, V. R.
    AMERICAN JOURNAL OF TRANSPLANTATION, 2011, 11 : 297 - 297